Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
The CD19/CD20 CAR/TRuC-T cell therapy is positioned to address a significant unmet need in the treatment of relapsed/refractory B-cell lymphoma, a market characterized by high demand for innovative therapies. The trial, sponsored by Shenzhen University General Hospital, aims to evaluate both the safety and efficacy of this dual-targeting approach, which may enhance therapeutic outcomes compared to existing CAR-T therapies. Given the increasing prevalence of B-cell malignancies and the limitations of current treatments, successful trial results could lead to a competitive advantage in a rapidly evolving market. The asset's development aligns with the growing trend towards personalized medicine and advanced cell therapies, potentially attracting interest from strategic partners and investors.
Indication: Relapsed/Refractory B-cell Lymphoma
Modality: combination therapy
Target: CD19 and CD20 antigens on B-cell lymphoma cells
Sponsor: Shenzhen University General Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 and CD20 antigens on B-cell lymphoma cells
View original source fields
Condition raw: Relapsed/Refractory B-cell Lymphoma
Condition normalized: Relapsed/Refractory B-cell Lymphoma
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: CD19 and CD20 antigens on B-cell lymphoma cells
Target normalized: CD19 and CD20 antigens on B-cell lymphoma cells